Taxol and vinorelbine: a new active combination for disseminated malignant melanoma.

Abstract:

:We evaluated the activity and toxicity of two sequences of taxol combined with vinorelbine in disseminated malignant melanoma, metastatic beyond regional lymph nodes. Fifteen previously untreated patients, nine males and six females (median age 56 years), were enlisted between May 1994 and February 1995. Eight patients received vinorelbine 30 mg/m2 (maximum dose 50 mg) first, follow 24 h later by taxol 120 mg/m2 (maximum dose 240 mg) infused over 3 h (the V/T sequence). Seven patients received the reverse (T/V) sequence. In 79 administered courses there were no anaphylactic episodes, the main toxicity being alopecia (WHO grade 3). Significant neutropenia, emesis or neuropathy was not observed in either schedule (WHO grades 0 or 1). Three major responses, all with the V/T sequences, were seen; one complete (CR) in nodal and cutaneous sites lasting 13 months and two partial (PR), omental, ascites in one and hepatic, splenic and nodal in the other, lasting 7 and 6 months, respectively. Clinically meaningful tumor regressions, not qualifying strictly for the criteria of major response, were observed in two additional patients in the T/V sequence. Taxol combined with vinorelbine is active against disseminated malignant melanoma. The importance of sequencing the two drugs remains to be determined with accrual of more patients into the study.

journal_name

Anticancer Drugs

journal_title

Anti-cancer drugs

authors

Retsas S,Mohith A,Mackenzie H

doi

10.1097/00001813-199602000-00003

subject

Has Abstract

pub_date

1996-02-01 00:00:00

pages

161-5

issue

2

eissn

0959-4973

issn

1473-5741

journal_volume

7

pub_type

临床试验,杂志文章
  • Potential antineoplastic activity of keto-C-glycosides--a new family of cytostatic agents.

    abstract::We have examined the biological activity of keto-C-glycosides (KCGs), a new family of drugs displaying antiproliferative and cytotoxic properties on tumor cells. KCG1, the most powerful drug tested on epithelial derived neoplastic cells, was 25-125 times more cytostatic on epithelial cells than on lymphoma. By contras...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-199208000-00006

    authors: Bennani-Baïti MI,Lafarge-Frayssinet C,Herscovici J,Monserret R,Antonakis K,Frayssinet C,Uriel J

    更新日期:1992-08-01 00:00:00

  • Nature as a remarkable chemist: a personal story of the discovery and development of Taxol.

    abstract::The development of a new anticancer drug with a novel structure and unique mechanism of action is an important event, especially when the drug plays a clear role in improving the outcome for cancer patients. No drug fits this description better than Taxol. However, during the early phases of its development, there was...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章,评审

    doi:10.1097/CAD.0000000000000063

    authors: Wani MC,Horwitz SB

    更新日期:2014-05-01 00:00:00

  • Comparison of the effect of the antiandrogen apalutamide (ARN-509) versus bicalutamide on the androgen receptor pathway in prostate cancer cell lines.

    abstract::Apalutamide (ARN-509) is an antiandrogen that binds selectively to androgen receptors (AR) and does not show antagonist-to-agonist switch like bicalutamide. We compared the activity of ARN versus bicalutamide on prostate cancer cell lines. The 22Rv1, PC3, and DU145 cell lines were used to study the effect of ARN and b...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000592

    authors: Koukourakis MI,Kakouratos C,Kalamida D,Mitrakas A,Pouliliou S,Xanthopoulou E,Papadopoulou E,Fasoulaki V,Giatromanolaki A

    更新日期:2018-04-01 00:00:00

  • Anticancer activities of alkylating pyrrole-imidazole polyamides with specific sequence recognition.

    abstract::In recent years, many diseases including cancer and hereditary and viral diseases have been understood at the DNA sequence level. Direct control of the expression level of a specific gene would provide a promising approach for knowledge-based therapy. N-methylpyrrole and N-methylimidazole polyamides are a new type of ...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章,评审

    doi:10.1097/CAD.0b013e328334d8f9

    authors: Shinohara K,Bando T,Sugiyama H

    更新日期:2010-03-01 00:00:00

  • Effects of oxymatrine on the apoptosis and proliferation of gallbladder cancer cells.

    abstract::Gallbladder carcinoma is the most common malignancy of the biliary tract and is associated with a very poor outcome. The aim of the present study was to investigate the effects of oxymatrine (OM) on gallbladder cancer cells and the possible mechanism of its effects. The effects of OM on the proliferation of gallbladde...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000124

    authors: Wu XS,Yang T,Gu J,Li ML,Wu WG,Weng H,Ding Q,Mu JS,Bao RF,Shu YJ,Cao Y,Wang XA,Ding QC,Dong P,Xie SF,Liu YB

    更新日期:2014-10-01 00:00:00

  • New formulation of 5-fluorouracil in microspheres reduces toxicity in mice.

    abstract::A new dosage formulation of 5-fluorouracil incorporated in microspheres (5-FU-MS) was developed for the treatment of peritoneal carcinomatosis. We studied the acute toxicity and side effects of i.p. 5-FU-MS in mice. The 50% lethal dose value for 5-FU-MS was 535.4 mg/kg of 5-FU, which was 2.22 times that of the aqueous...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-199609000-00010

    authors: Hagiwara A,Sakakura C,Tsujimoto H,Ohgaki M,Imanishi T,Yamazaki J,Sawai K,Takahashi T,Yamamoto A,Muranishi S,Tabata Y,Ikada Y

    更新日期:1996-09-01 00:00:00

  • Augmentation of antiproliferative activity of CPT-11, a new derivative of camptothecin, by tumor necrosis factor against proliferation of gynecologic tumor cell lines.

    abstract::The co-operative effects of recombinant human tumor necrosis factor (rH-TNF) and CPT-11, a new derivative of camptothecin, against the proliferation of human gynecologic tumor cell lines were examined in vitro. The ishikawa cells were responsive to rH-TNF, the HHUA cells exhibited a minimal degree of responsiveness to...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-199110000-00006

    authors: Mori H,Sawairi M,Itoh N,Hanabayashi T,Kondoh H,Tamaya T

    更新日期:1991-10-01 00:00:00

  • Phase 1 study of escalating-dose OncoGel (ReGel/paclitaxel) depot injection, a controlled-release formulation of paclitaxel, for local management of superficial solid tumor lesions.

    abstract::OncoGel is a novel depot formulation of paclitaxel designed for intralesional injection with a sustained paclitaxel delivery over approximately 6 weeks from a single administration. This phase 1 study was designed to characterize the toxicity, pharmacokinetics and preliminary antitumor activity associated with OncoGel...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e328011a51d

    authors: Vukelja SJ,Anthony SP,Arseneau JC,Berman BS,Cunningham CC,Nemunaitis JJ,Samlowski WE,Fowers KD

    更新日期:2007-03-01 00:00:00

  • A case of glassy cell carcinoma of the uterine cervix effectively responding to chemotherapy with paclitaxel and carboplatin.

    abstract::Glassy cell carcinoma (GCC) of the uterine cervix is a highly malignant tumor and has a poor prognosis. As yet, no effective systemic chemotherapy to this tumor has been reported. Here we describe a case of recurrent GCC that responded to paclitaxel and carboplatin combination treatment. The patient, a 32-year-old wom...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-200108000-00010

    authors: Hirashima Y,Kobayashi H,Nishiguchi T,Miura K,Kanayama N

    更新日期:2001-08-01 00:00:00

  • Cytotoxic effects of the trifunctional bispecific antibody FBTA05 in ex-vivo cells of chronic lymphocytic leukaemia depend on immune-mediated mechanism.

    abstract::Monoclonal antibodies such as rituximab and alemtuzumab show considerable therapeutic efficacy in chronic lymphocytic leukaemia (CLL). Aiming to further improve antineoplastic efficacy, the trifunctional bispecific antibody FBTA05 was developed. FBTA05 is thought to function by simultaneously binding B cells and T cel...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e328344887f

    authors: Boehrer S,Schroeder P,Mueller T,Atz J,Chow KU

    更新日期:2011-07-01 00:00:00

  • 1,4-Anthraquinone: an anticancer drug that blocks nucleoside transport, inhibits macromolecule synthesis, induces DNA fragmentation, and decreases the growth and viability of L1210 leukemic cells in the same nanomolar range as daunorubicin in vitro.

    abstract::1,4-Anthraquinone (AQ) was synthesized and shown to prevent L1210 leukemic cells from synthesizing macromolecules and growing in vitro. In contrast, its dihydroxy-9,10anthraquinone precursor, quinizarin, was inactive. The antitumor activity of AQ was compared to that of daunorubicin (DAU), which is structurally differ...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-200006000-00004

    authors: Perchellet EM,Magill MJ,Huang X,Dalke DM,Hua DH,Perchellet JP

    更新日期:2000-06-01 00:00:00

  • Para-toluenesulfonamide induces tongue squamous cell carcinoma cell death through disturbing lysosomal stability.

    abstract::Para-toluenesulfonamide (PTS) has been implicated with anticancer effects against a variety of tumors. In the present study, we investigated the inhibitory effects of PTS on tongue squamous cell carcinoma (Tca-8113) and explored the lysosomal and mitochondrial changes after PTS treatment in vitro. High-performance liq...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000283

    authors: Liu Z,Liang C,Zhang Z,Pan J,Xia H,Zhong N,Li L

    更新日期:2015-11-01 00:00:00

  • Gene expression profiles as biomarkers for the prediction of chemotherapy drug response in human tumour cells.

    abstract::Genome profiling approaches such as cDNA microarray analysis and quantitative reverse transcription polymerase chain reaction are playing ever-increasing roles in the classification of human cancers and in the discovery of biomarkers for the prediction of prognosis in cancer patients. Increasing research efforts are a...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章,评审

    doi:10.1097/CAD.0b013e3280262427

    authors: Parissenti AM,Hembruff SL,Villeneuve DJ,Veitch Z,Guo B,Eng J

    更新日期:2007-06-01 00:00:00

  • Evaluation of [131I]iodoerythronitroimidazole as a predictor for the radiosensitizing effect.

    abstract::The aim of this study was to evaluate whether radiolabeled iodoerythronitroimidazole (IETNIM) could predict the radiosensitization effect on tumors. Tumor-bearing mice were irradiated at a dose of 25, 31 and 37 Gy after the injection of IETNIM. They were also exposed to 37 Gy radiation at 35, 70, 140 and 240 min after...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-199611000-00007

    authors: Inoue T,Yang DJ,Wallace S,Cherif A,Tansey W,Kim EE,Hunter N,Milross CG,Milas L,Podoloff DA

    更新日期:1996-11-01 00:00:00

  • Preclinical toxicologic evaluation of DENSPM (N1,N11-diethylnorspermine) in rats and dogs.

    abstract::A toxicology study of DENSPM was carried out in rats by multiple (once daily for 5 days) intravenous injection. Doses of 12.5, 25 and 50 mg DENSPM/kg were well tolerated. Infusion of 100 mg DENSPM resulted in distressing physical signs, including labored breathing, convulsive movements and acute death. There were no e...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-199408000-00010

    authors: Kanter PM,Bullard GA,King JM

    更新日期:1994-08-01 00:00:00

  • Isoquercitrin isolated from Hyptis fasciculata reduces glioblastoma cell proliferation and changes beta-catenin cellular localization.

    abstract::Isoquercitrin isolated from the aerial parts of Hyptis fasciculata was evaluated according to its capacity to interfere with glioblastoma (Gbm) cell growth. Gbm cells were incubated with isoquercitrin, quercetin, or rutin at concentrations of 25, 50, and 100 mumol/l for 24, 48, and 72 h. Quercetin and rutin affected G...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e32832d1149

    authors: Amado NG,Cerqueira DM,Menezes FS,da Silva JF,Neto VM,Abreu JG

    更新日期:2009-08-01 00:00:00

  • Gene expression changes during the development of estrogen-independent and antiestrogen-resistant growth in breast cancer cell culture models.

    abstract::We have established estrogen-independent and antiestrogen-resistant cell lines from hormone-dependent MCF-7 breast cancer cells by long-term culture in the absence of estrogen, or in the presence of antiestrogen toremifene, respectively. By using a cDNA microarray we compared gene expression profiles among estrogen-in...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e32831845e1

    authors: Pennanen PT,Sarvilinna NS,Ylikomi TJ

    更新日期:2009-01-01 00:00:00

  • Biochemical and molecular effects of UCN-01 in combination with 5-fluorodeoxyuridine in A431 human epidermoid cancer cells.

    abstract::Concurrent and pre-exposure of A431 human epidermoid cancer cells to UCN-01, an investigational anticancer drug, with 5-fluoro--2'-deoxyuridine (FdUrd), which targets thymidylate synthase, produced more than additive cytotoxicty. A 24-h exposure to 10 nM FdUrd led to inhibition of TS, a 2.5-fold increase in total thym...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-200203000-00008

    authors: Grem JL,Danenberg KD,Kao V,Danenberg PV,Nguyen D

    更新日期:2002-03-01 00:00:00

  • Tamoxifen as a potential treatment of glioma.

    abstract::Cerebral gliomas have a poor survival time even after multimodal treatment, because of the unavoidable recurrence of tumor. Several trials with a combination of old and new chemotherapics have been performed, but survival time remains generally less than 12 months. Tamoxifen (TAM) has recently been shown to inhibit th...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章,评审

    doi:10.1097/00001813-199808000-00001

    authors: Mastronardi L,Puzzilli F,Ruggeri A

    更新日期:1998-08-01 00:00:00

  • A suramin derivative induces enterocyte-like differentiation of human colon cancer cells without lysosomal storage disorder.

    abstract::Suramin is a polysulfonated naphthylurea currently investigated for the treatment of advanced malignancy. We have previously reported that suramin was a potent inducer of the differentiation of the human colic adenocarcinoma cell clone HT29-D4 (Fantini et al., J Biol Chem, 1989; 264: 10282-10286). In this report, we s...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-199010000-00011

    authors: Baghdiguian S,Nickel P,Marvaldi J,Fantini J

    更新日期:1990-10-01 00:00:00

  • Exploring the lack of cross-resistance between aromatase inhibitors: evidence for a difference?

    abstract::A lack of cross-resistance between the aromatase inhibitors (AIs) provides evidence to suggest that there are clinical differences between these agents. Available data from clinical trials indicate that patients exposed to nonsteroidal AIs may benefit from a steroidal compound of similar biochemical potency, and durab...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章,评审

    doi:10.1097/01.cad.0000277875.81122.25

    authors: Lønning PE

    更新日期:2008-03-01 00:00:00

  • Down-regulation of human topoisomerase IIalpha correlates with altered expression of transcriptional regulators NF-YA and Sp1.

    abstract::Topoisomerase IIalpha (Topo IIalpha) is an essential nuclear enzyme with a role in the maintenance of DNA topology. Topo IIalpha is a target for several anticancer drugs and the levels of activity of this enzyme have been implicated in the development of drug resistance. Our objective was to identify regulatory transc...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-200404000-00008

    authors: Allen KA,Williams AO,Isaacs RJ,Stowell KM

    更新日期:2004-04-01 00:00:00

  • Phase I trial of weekly irinotecan and paclitaxel combined with carboplatin in patients with advanced cancer: a Hellenic Cooperative Oncology Group Study.

    abstract::This trial aimed to define a recommended safe dose (RSD) of weekly paclitaxel and irinotecan combined with carboplatin in patients with advanced cancer. Patients with advanced cancer were eligible for this trial. Dose-limiting toxicity (DLT) was considered to be any grade greater than or equal to 3 (G> or =3) nonhemat...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e32833d5ec0

    authors: Briasoulis E,Golfinopoulos V,Karina M,Papakostas P,Pavlidis N,Fountzilas G

    更新日期:2010-09-01 00:00:00

  • A phase II study of an oxaliplatin/vinorelbine/5-fluorouracil combination in patients with anthracycline-pretreated and taxane-pretreated metastatic breast cancer.

    abstract::The aim of this phase II study was to evaluate safety and efficacy of an oxaliplatin/vinorelbine/5-fluorouracil (FON) combination in anthracycline and taxane-pretreated metastatic breast cancer patients. The following treatment was given: on day 1 of a 21-day cycle, oxaliplatin 130 mg/m (2-h intravenous infusion); on ...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/01.cad.0000231475.77159.aa

    authors: Delozier T,Guastalla JP,Yovine A,Levy C,Chollet P,Mousseau M,Delva R,Coeffic D,Vannetzel JM,Zazzi ES,Brienza S,Cvitkovic E

    更新日期:2006-10-01 00:00:00

  • The clinical rationale for developing docetaxel (Taxotere).

    abstract::Clinical empiricism has recognized resistant breast cancer as a privileged target for docetaxel (Taxotere). This worldwide registration will offer medical oncologists the opportunity to develop new indications for docetaxel. Pharmacokinetics, preclinical optimal combination and clinical practice will constitute the ra...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章,评审

    doi:

    authors: Armand JP

    更新日期:1996-08-01 00:00:00

  • Effects of Taxotere and taxol on in vitro colony formation of freshly explanted human tumor cells.

    abstract::Taxotere (RP 56976, NSC 628503) is a new semisynthetic analog of taxol (NSC 125973) with promising antitumor activity in a variety of preclinical screening systems. Clinical responses after treatment with taxol have been observed in ovarian cancer, breast, lung cancer and melanoma. Both agents act through induction of...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-199204000-00008

    authors: Hanauske AR,Degen D,Hilsenbeck SG,Bissery MC,Von Hoff DD

    更新日期:1992-04-01 00:00:00

  • LC-based targeted metabolomics analysis of nucleotides and identification of biomarkers associated with chemotherapeutic drugs in cultured cell models.

    abstract::Treatment of mammalian cells with chemotherapeutic drugs can result in perturbations of nucleotide pools. Monitoring these perturbations in cultured tumor cells from human sources is useful for assessment of the effect of drug therapy and a better understanding of the mechanism of action of these drugs. In this study,...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000096

    authors: Liu X,Zhang CC,Liu Z,Wei L,Liu YJ,Yu J,Sun LX

    更新日期:2014-07-01 00:00:00

  • beta-Lapachone-induced apoptosis is associated with activation of caspase-3 and inactivation of NF-kappaB in human colon cancer HCT-116 cells.

    abstract::beta-Lapachone is a naturally occurring quinone obtained from the bark of the lapacho tree (Tabebuia avellanedae) with cancer chemopreventive properties. The objective of the present study was to investigate the effect of beta-lapachone on the cell growth and apoptosis in human colon carcinoma tumor cell line HCT-116....

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-200311000-00011

    authors: Choi BT,Cheong J,Choi YH

    更新日期:2003-11-01 00:00:00

  • Mechanism of action of rituximab.

    abstract::The CD20 antigen is strongly and stably expressed on cells of the B-cell lineage, but not on stem cells, and is thus an ideal target antigen for antibody therapy of B-cell malignancies. Rituximab is a human-mouse chimeric monoclonal antibody to the CD20 antigen that kills B-cells by a number of different effector mech...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章,评审

    doi:

    authors: Maloney DG

    更新日期:2001-06-01 00:00:00

  • Phase I/II study of irinotecan (CPT-11) and S-1 in the treatment of advanced gastric cancer.

    abstract::A phase I/II study to determine the recommended dose for combination therapy with CPT-11 (irinotecan hydrochloride) and S-1 (tegafur, gimestat and otastat potassium) for advanced or recurrent gastric cancer, and to assess the safety and efficacy of this therapy. In the phase I portion of the study, S-1 was administere...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e3280262460

    authors: Katsube T,Ogawa K,Ichikawa W,Fujii M,Tokunaga A,Takagi Y,Kochi M,Hayashi K,Kubota T,Aiba K,Arai K,Terashima M,Kitajima M

    更新日期:2007-06-01 00:00:00